aibioSoligenix regains Nasdaq stockholders' equity compliance after August notice
Tickers SNGX
Nasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.
Key facts
- Company
- Soligenix, Inc. (NASDAQ: SNGX)
- News type
- Listings
- Primary source
- SOLIGENIX, INC. Form 8-K filed November 18, 2025 (SEC EDGAR)
Soligenix, Inc. (Nasdaq: SNGX) said on November 18, 2025 that Nasdaq has confirmed it regained compliance with the minimum stockholders' equity requirement for continued listing, and that the matter is closed. The company disclosed the news in a Form 8-K filed with the SEC. The relief follows a notice in August and comes from a company whose last annual report carried a going-concern warning.
What the filing says
On November 18, 2025, Soligenix received a letter from The Nasdaq Stock Market LLC confirming that it had regained compliance with the Shareholders' Equity Requirement and that the matter is now closed. The 8-K is short. It gives no new balance sheet, no financing and no explanation of how equity rose above the minimum.
The earlier Nasdaq notice
On August 15, 2025, Soligenix received a written notice from Nasdaq advising that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies on that market to maintain stockholders' equity of at least $2,500,000.
In its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, the company reported stockholders' equity of $7,597,976, which the filing says is above the requirement. The 8-K does not say what changed between the August notice and that report.
The going-concern backdrop
Soligenix's annual report on Form 10-K, filed March 21, 2025, describes a thinner position at the end of 2024. The company reported an accumulated deficit of approximately $234.0 million at December 31, 2024. It had approximately $7.8 million in cash and cash equivalents and current liabilities of approximately $4.8 million at that date, and approximately $7.7 million in cash as of March 14, 2025.
The 10-K says its losses from operations, negative cash flows and shareholders' deficit as of December 31, 2024 raise substantial doubt about its ability to continue as a going concern absent new debt or equity financing. The report of its independent registered accounting firm contains an explanatory paragraph on the same point. The company said it expected to maintain its current level of operations to the end of 2025 without additional funding, and management said it had resources into the fourth quarter of 2025. Its plans to alleviate the doubt include raising equity or doing strategic deals, and additional proceeds from government contract and grant programs.
About the company
Soligenix describes itself as a late-stage biopharmaceutical company focused on rare diseases with unmet medical need. It has two segments, Specialized BioTherapeutics and Public Health Solutions.
The lead program is HyBryte, a topical synthetic hypericin activated with visible light, for cutaneous T-cell lymphoma (CTCL). The company says its first Phase 3 FLASH study, which enrolled 169 patients with 166 evaluable, met its primary endpoint with a p-value of 0.04 at eight weeks. A total of 16% of patients on HyBryte reached at least a 50% reduction in index lesions, against 4% on placebo. Response rates were low in both groups. A confirmatory Phase 3 study, FLASH2, began enrolling in December 2024, with top-line results anticipated in the second half of 2026.
Other programs include synthetic hypericin (SGX302) for psoriasis and dusquetide (SGX942 and SGX945), which the company calls a first-in-class Innate Defense Regulator, for oral mucositis in head and neck cancer and aphthous ulcers in Behçet's Disease. The Public Health Solutions segment includes RiVax, a ricin toxin vaccine candidate, and SGX943 for antibiotic resistant and emerging infectious disease, supported by government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.
Who signed
Christopher J. Schaber, Ph.D., President and Chief Executive Officer, signed the 8-K for Soligenix.